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Summary
 
Pristane induces a lupus-like syndrome in nonautoimmune mice characterized by the develop-
ment of glomerulonephritis and lupus-associated autoantibodies. This is accompanied by over-
production of interleukin (IL)-6, a cytokine linked with autoimmune phenomena. The goal of
this study was to evaluate the role of IL-6 in autoantibody production in pristane-induced lu-
pus. BALB/cAn IL-6–deficient (
 
2/2
 
) and –intact (
 
1/1
 
) mice were treated with pristane or
phosphate-buffered saline, and autoantibody production was evaluated. Pristane induced high
levels of immunoglobulin (Ig)G anti-single-stranded DNA, –double-stranded (ds)DNA, and
-chromatin antibodies in IL-6
 
1/1
 
, but not IL-6
 
2/2
 
 mice by enzyme-linked immunosorbent as-
say. High titer IgG anti-dsDNA antibodies also were detected in sera from 
 
1/1
 
, but not 
 
2/2
 
,
mice by 
 
Crithidia luciliae
 
 kinetoplast staining. The onset of IgG anti-dsDNA antibody produc-
tion in 
 
1/1
 
 mice occurred 
 
.
 
5 mo after pristane treatment, well after the onset of nephritis,
suggesting that these antibodies are not directly responsible for inducing renal disease. In con-
trast to anti-DNA, the frequencies of anti-nRNP/Sm and anti-Su antibodies were similar in
pristane-treated IL-6
 
2/2
 
 and IL-6
 
1/1
 
 mice. However, levels were higher in the 
 
1/1
 
 group.
These results suggest that IgG anti-DNA and chromatin antibodies in pristane-treated mice are
strictly IL-6 dependent, whereas induction of anti-nRNP/Sm and Su autoantibodies is IL-6
independent. The IL-6 dependence of anti-DNA, but not anti-nRNP/Sm, may have implica-
tions for understanding the patterns of autoantibody production in lupus. Anti-DNA antibod-
ies are produced transiently, mainly during periods of disease activity, whereas anti-nRNP/Sm
antibody levels are relatively insensitive to disease activity. This may reflect the differential IL-6
dependence of the two responses.
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ALB/c, SJL/J, and C57BL/6 mice injected intraperi-
toneally with pristane develop lupus-specific autoanti-
bodies, including anti-nRNP/Sm and ribosomal P, as well
as the less disease-specific autoantibodies anti-Su, histone,
and single-stranded (ss)DNA (1–3). They also develop se-
vere immune complex–mediated glomerulonephritis start-
ing 4–6 mo after pristane treatment (2, 3). Anti–double-
stranded (ds)DNA antibodies, which are implicated in the
pathogenesis of lupus nephritis (4, 5), have so far not been
observed, raising questions about the role of anti-dsDNA
antibodies in the development of nephritis in these mice.
IL-6 production by an expanded macrophage compart-
ment is thought to be instrumental in the pathogenesis of
anti-DNA antibodies and nephritis in (NZB/W)F1 mice (6,
7). In light of these findings and the fact that large amounts of
IL-6 are produced upon uptake of pristane by murine perito-
neal macrophages (8, 9), we investigated the role of this
cytokine in autoantibody production in pristane-induced lu-
pus. Our data indicate that production of IgG anti-ssDNA,
antichromatin and anti-dsDNA antibodies in pristane-treated
mice requires IL-6, suggesting that anti-DNA antibody pro-
duction in lupus is a marker of IL-6 overproduction. Unex-
pectedly, the frequencies of anti-nRNP/Sm and Su autoanti-
bodies were similar in IL-6 deficient versus intact mice,
suggesting that pristane induces autoantibody production by
both IL-6–independent and –dependent pathways.
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Materials and Methods
 
Mice.
 
Mice were generated by five backcrosses of B6/129SV
IL-6
 
2/2
 
 with BALB/cAn. Mice heterozygous for the IL-6 muta-
tion were intercrossed to create IL-6
 
2/2
 
 and IL-6
 
1/1
 
 mice and
were genotyped by Southern blotting (10). Female BALB/cAn
IL-6
 
2/2
 
 (
 
n
 
 
 
5 
 
28) and IL-6
 
1/1
 
 (
 
n
 
 
 
5 
 
26) mice, age 10–12 wk, were
injected once intraperitoneally with 0.5 ml of pristane (2,6,10,14-
tetramethylpentadecane; Sigma Chemical Co., St. Louis, MO)
(1). Control mice (IL-6
 
2/2
 
,
 
 n 
 
5 
 
10 and IL-6
 
1/1
 
,
 
 n 
 
5 
 
10) received
0.5 ml of PBS intraperitoneally. Sera were collected from the tail
vein before treatment, at 3 wk, and at 3, 5, and 8 mo after treatment.
Mice were housed under specific pathogen–free conditions.
 
Immunoprecipitation.
 
Analysis of autoantibody specificities by
immunoprecipitation was carried out as described previously (1).
 
ELISAs.
 
Antigen capture ELISAs for anti-nRNP/Sm and
anti-Su antibodies were performed as described, using mouse sera
at a dilution of 1:500 and goat anti–mouse IgG second antibodies
(
 
g 
 
chain–specific, from Southern Biotechnology Associates, Bir-
mingham, AL) (11, 12). Anti-ssDNA ELISA was performed as
previously described (13), and data were analyzed using the Mann
Whitney test.
Anti-dsDNA antibody ELISA was carried out as previously
described with minor modifications (14). In brief, calf thymus
DNA (Sigma Chemical Co.) was extracted with phenol/chloro-
form/isoamyl alcohol and digested with S1 nuclease (GIBCO
BRL, Gaithersburg, MD). Dynex polystyrene microtiter plates
(Dynastar, Dynatech, Chantilly, VA) were coated with 100 
 
m
 
l/
well of 5 
 
m
 
g/ml DNA in SSC, pH 8.0, and incubated at 37
 
8
 
C for
12 h. Sera were tested at a 1:160 dilution followed by alkaline
phosphatase–conjugated goat anti–mouse IgG antibodies. Sub-
strate was added, and A
 
405 nm
 
 was determined. Absorbances from
blank wells (no serum added) were subtracted.
IgG antichromatin antibodies were measured as previously de-
scribed (15). In brief, polyvinyl chloride microtiter plates were
coated with 10 
 
m
 
g/ml chicken erythrocyte chromatin in borate-
buffered saline. Sera were tested at a 1:500 dilution, followed by
biotinylated goat anti–mouse IgG (pFc
 
9
 
-specific, 1:4,000 dilu-
tion, from Dr. P.L. Cohen, University of North Carolina, Divi-
sion of Rheumatology and Immunology), avidin-conjugated al-
kaline phosphatase (Zymed Labs, South San Francisco, CA), and
 
p
 
-nitrophenyl phosphate substrate. The A
 
405 nm
 
 of a 1:1,000 dilu-
tion of a high titer MRL/
 
lpr
 
 reference serum was assigned a value
of 2,048 units, and a 2
 
11
 
-fold dilution of this standard a value of 2
units (15). IgG antichromatin activity in units for each sample was
determined as in reference 12.
 
Fluorescence Assay for Anti-dsDNA Antibodies.
 
Anti-dsDNA anti-
bodies were measured by the 
 
Crithidia luciliae
 
 kinetoplast staining
assay (16) at a serum dilution of 1:20 according to the manufac-
turer’s instructions (The Binding Site, Birmingham, UK). Second
antibody was FITC-conjugated goat anti–mouse IgG (1:40 dilu-
tion; Southern Biotechnology Associates). All positive sera were
titered (1:40, 1:80, 1:160, 1:320, and 1:640 dilutions).
 
Results and Discussion
 
IL-6 has been implicated in both anti-DNA antibody
production and the pathogenesis of nephritis in (NZB/
W)F1 mice (6, 7), and in the development of autoantibod-
ies in patients with cardiac myxomas (17, 18). It also is es-
sential for the growth of plasmacytomas in pristane-treated
mice (8, 19–21). This study was undertaken to evaluate the
role of this cytokine in the induction of autoantibodies by
pristane in BALB/c mice.
 
Anti-DNA Antibody Production in Pristane-induced Lupus.
 
The production of IgM anti-ssDNA antibodies 2–3 wk after
treating BALB/c mice with pristane (2) appears to be thymus-
independent (reference 2 and Richards, H.B., M. Satoh,
J.C. Jennette, T. Okano, Y.S. Kanwar, and W.H. Reeves,
manuscript submitted for publication). Because IL-6 can
stimulate T cell–independent Ig production (22, 23), the
induction of IgM anti-ssDNA antibodies by pristane in
BALB/cAn IL-6
 
2/2
 
 and IL-6
 
1/1
 
 mice was investigated.
As shown in Fig. 1, IgM anti-ssDNA antibody levels
were similar in IL-6
 
2/2
 
 versus IL-6
 
1/1
 
 mice 3 wk after pris-
tane treatment. In contrast, IgG anti-ssDNA antibodies
were detected at a high frequency 8 mo after pristane treat-
ment only in IL-6
 
1/1
 
 mice (
 
P
 
 
 
, 
 
0.05 versus IL-6
 
2/2
 
 by
Mann Whitney test).
Anti-dsDNA antibodies are highly specific for lupus and
are implicated in the pathogenesis of lupus nephritis. How-
ever, they were not detected previously in the 6-mo sera
from pristane-treated BALB/c mice, a time when severe
renal lesions already were apparent (2). In contrast, sera
from 10 out of 26 BALB/cAn (IL-6
 
1/1
 
) mice (38%) 8 mo
after pristane treatment were strongly positive for anti-
dsDNA antibodies by 
 
Crithidia luciliae
 
 kinetoplast staining
(Table 1) at titers ranging from 1:80 to 1:640 (Table 2).
Anti-dsDNA antibodies were not detected in pristane-
treated IL-6
 
2/2
 
 mice or PBS-treated IL-6
 
1/1
 
 or IL-6
 
2/2
 
mice (Table 1). Although the 
 
Crithidia luciliae
 
 kinetoplast
staining assay is highly specific for anti-dsDNA activity, oc-
casionally antihistone antibodies give a false positive reac-
tion. To exclude that possibility, the sera were tested for
Figure 1. Anti-ssDNA and anti-
dsDNA autoantibody levels. (left)
Sera from BALB/cAn IL-62/2 or
IL-61/1 mice 3 wk after pristane or
PBS treatment were tested by
ELISA for IgM anti-ssDNA anti-
bodies at a dilution of 1:500. Sera
from the same mice 8 mo after
treatment were tested by ELISA for
IgG anti-ssDNA antibodies. Sym-
bols represent individual animals
and horizontal lines represent the mean A405 nm of each group (*P , 0.005 in the IL-61/1 pristane versus IL-62/2 pristane by Mann Whitney test). (right)
Sera from BALB/cAn mice 8 mo after pristane or PBS treatment, 5-mo-old MRL/lpr mice, and mAb 6/O2 576-2 (IgG anti-ssDNA) were analyzed by
ELISA for IgG anti-dsDNA antibodies at a 1:160 dilution. Samples were negative (d) or positive (h) positive by Crithidia assay at a 1:40 dilution. 
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IgG anti-dsDNA antibodies by ELISA. The ELISA was
somewhat less sensitive than the fluorescence assay, since
only sera with titers 
 
.
 
1:640 gave a significantly stronger
reaction by ELISA than the 
 
Crithidia
 
-negative group. An
anti-ssDNA mAb (6/O2 576-2; from Dr. D. Pisetsky,
Duke University, Durham, NC) also showed weak ELISA
reactivity. Remarkably, none of the sera from pristane-
treated IL-6
 
2/2
 
 mice bound to S1 nuclease-treated DNA at
8 mo (Fig. 1).
Together, these results indicate that pristane-treated
BALB/cAn mice develop high levels of IgG anti-ssDNA
and anti-dsDNA antibodies, and that these autoantibodies
are IL-6 dependent. However, the appearance of these au-
toantibodies is delayed until 8 mo after treatment, which is
after the onset of renal disease. Some of the pristane-treated
BALB/cAn mice developed IgG anti-dsDNA antibodies at
levels comparable to those in MRL/
 
lpr
 
 mice (Table 2, Fig.
1). Although it has been suggested that anti-dsDNA anti-
body production can result from polyclonal B cell activation
(24), the marked polyclonal hypergammaglobulinemia seen
in both IL-6
 
1/1
 
 and IL-6
 
2/2
 
 mice 3–5 mo after pristane
treatment was not accompanied by an anti-dsDNA response,
suggesting that other mechanisms may be more important in
generating these autoantibodies. These may include effects of
IL-6 on terminal B cell differentiation (17, 25).
 
IgG Antichromatin Antibodies.
 
Like anti-dsDNA, anti-
chromatin antibodies are found at high levels in MRL/
 
lpr
 
and other lupus mice (15, 26). Anti-DNA responses are
linked to the immune response to chromatin, since T cells
specific for histones can help B cells producing anti-DNA
antibodies (27). Thus, it was of interest to see if antichro-
matin and anti-DNA antibodies exhibit similar IL-6 depen-
dence. Pristane induced high levels of IgG antichromatin
antibodies within 3–5 mo, but only in BALB/cAn IL-6
 
1/1
 
mice (Figs. 2 and 3, 
 
C
 
 and 
 
D
 
). Interestingly there was low
level spontaneous production of these autoantibodies in
aged IL-6
 
1/1
 
 PBS-treated mice (Fig. 2), which was absent
in IL-6
 
2/2
 
 animals. Thus, IL-6 may be important for the
production of pristane-induced, as well as spontaneous,
IgG antichromatin autoantibodies.
Since IL-6 plays an important role in the differentiation
of antigen plus CD40 coactivated B cells into antibody-
secreting cells (28), the lack of IgG anti-DNA/chromatin
autoantibodies in IL-6-deficient mice may reflect an abso-
lute requirement for IL-6 in the differentiation of germinal
center B cells into anti-DNA/chromatin secreting plasma
cells. This interpretation is consistent with previous obser-
vations that IL-6 is crucial for the development of anti-
DNA/chromatin antibodies in spontaneous murine lupus
models (6, 7) and that the production of these autoantibod-
ies also is dependent on CD40–CD40 ligand interactions
(29, 30). Rheumatoid factor is not produced in CD40
ligand–deficient MRL/
 
lpr
 
 mice either, whereas anti-
nRNP/Sm antibodies are (30), suggesting that the latter
may be regulated differently than anti-DNA and rheuma-
toid factor. Like anti-dsDNA, rheumatoid factor was in-
duced by pristane in IL-6
 
1/1
 
 but not IL-6
 
2/2
 
 mice (data
not shown), suggesting that similar regulatory mechanisms
may exist in pristane-induced lupus.
 
IgG Anti-nRNP/Sm and Anti-Su Antibodies.
 
The IL-6
dependence of IgG anti-DNA and chromatin autoantibod-
ies is consistent with previous observations in the (NZB/
 
Table 1.
 
Frequency of Autoantibodies in Pristane-treated
BALB/cAN Mice
 
Strain and Rx
No. of
mice
Anti-
nRNP/Sm
 
*
 
Anti-Su
 
*
 
Anti-
dsDNA
 
*
 
IL-6
 
2
 
/
 
2
 
 pristane 28 13 (46%) 10 (36%) 0
IL-6
 
2
 
/
 
2
 
 PBS 10 0 0 0
IL-6
 
1
 
/
 
1
 
 pristane 26 15 (58%) 8 (31%) 10 (38%)
IL-6
 
1
 
/
 
1
 
 PBS 10 0 0 0
 
*
 
Sera from BALB/cAn mice were tested 8 mo after treatment with
pristane or PBS. Anti-nRNP/Sm and Su antibodies were detected by
immunoprecipitation and their presence was confirmed by ELISA (Fig. 3).
Anti-dsDNA antibodies were detected in the sera by 
 
Crithidia luciliae
 
 ki-
netoplast staining at a dilution of 1:20.
 
Table 2. Titers of Anti-dsDNA Antibodies in Pristane-treated 
BALB/cAN IL-61/1 Mice*
Titer No. of mice
1:80 1
1:160 4
1:320 2
$1:640 3
*Crithidia luciliae kinetoplast staining assay.
Figure 2. IgG antichromatin antibody ELISA. Serial serum samples
from all pristane- or PBS-treated mice were analyzed at a dilution of
1:500 for IgG anti-chromatin antibodies by ELISA. Levels of IgG anti-
chromatin are expressed in units 3 106 (see Materials and Methods).988 IL-6 Effect on Anti–DNA Antibodies
W)F1 lupus model (6, 7). However, (NZB/W)F1 do not
produce other autoantibodies characteristic of lupus, such
as anti-nRNP/Sm. Thus, it is not known whether or not
the latter also are IL-6 dependent. This question was ad-
dressed in the pristane-induced lupus model, in which au-
toantibodies to both RNA-protein and DNA-protein au-
toantigens are produced.
In contrast to the absence of IgG anti-dsDNA and anti-
chromatin autoantibodies and in IL-62/2 mice (Figs. 1 and
2, Table 1), the frequencies of anti-nRNP/Sm autoanti-
bodies were comparable in the IL-62/2 and IL-61/1 mice
(Fig. 3 A, Table 1), although levels were lower in the
IL-62/2 mice (Fig. 3 B). Similarly, the frequencies of anti-
Su autoantibodies in IL-61/1 versus IL-62/2 mice were
comparable (Table 1). In agreement with the ELISA data,
both anti-nRNP/Sm and anti-Su autoantibodies were de-
tectable in the sera of IL-62/2 by immunoprecipitation of
35S-labeled cell extracts. We conclude that the induction of
anti-nRNP/Sm and Su autoantibodies is IL-6 indepen-
dent, whereas their levels are influenced by IL-6. Since
IgG2a was the predominant isotype of the anti-nRNP/Sm
and Su, as well as anti-dsDNA and -chromatin autoantibod-
ies (not shown), it is unlikely that the differential effects of
IL-6 on their induction reflects merely an altered ability to
produce antibodies of a particular isotype or isotypes. Fur-
thermore, analysis of total Ig levels revealed marked in-
creases in IgG2a, IgG2b, and IgG3 from 1 to 3 mo after
pristane treatment both in IL-61/1 and IL-62/2 mice (data
not shown). This was only slightly less dramatic in the
IL-62/2 group than in the IL-61/1 mice.
Although DNA binding is critical for the activation of a
subset of anti-Sm B cells (31), our data argue that the induc-
tion of anti-DNA and anti-Sm responses may be at least par-
tially independent processes. This also appears true in CD40
ligand–deficient mice (30). Whereas anti-DNA/chromatin is
CD40 and IL-6 dependent, anti-nRNP/Sm antibody pro-
duction may be enhanced via a T cell–dependent and CD40-
and IL-6–independent mechanism (Richards, H.B., M. Sa-
toh, J.C. Jennette, T. Okano, Y.S. Kanwar, and W.H.
Reeves, et al., manuscript submitted for publication). Certain
CD40 ligand–negative T cell clones retain the capacity to in-
duce plasma cell differentiation (32). Recently, it was shown
that the CD27–CD70 signaling pathway may promote B cell
differentiation into IgG-secreting plasma cells, whereas CD40
ligand–CD40 signaling may be more important for maintain-
ing B cell proliferation and differentiation into memory cells
(33, 34). The role of this or other pathways of CD40 ligand–
independent B cell activation in the generation of anti-
nRNP/Sm and Su antibodies remains to be determined.
IL-6 is thought to influence the development of sponta-
neous human and murine lupus. It may play a role in the
induction of autoantibodies (17) and nephritis (35, 36), as
well as in polyclonal B cell activation (37, 38). Polyclonal
hypergammaglobulinemia in lupus may reflect both the
overexpression of IL-6 receptors on B cells (37, 39) and, in
MRL/lpr mice, increasing IL-6 gene expression and serum
levels with age (40). Although increased IL-6 production in
MRL mice is related to the presence of the lpr gene, it is
not produced by the abnormal double negative T cells (40),
and may be derived from the expanded macrophage subset
of these mice (6, 41).
Summary and Clinical Implications. The goal of this study
was to examine the production of anti-dsDNA antibodies,
long considered to be a marker of lupus nephritis (4, 5), in
pristane-induced lupus. Anti-dsDNA antibodies were pro-
duced late in the course of pristane-induced lupus and were
strictly IL-6 dependent, possibly reflecting the IL-6 over-
production characteristic of pristane-treated mice (8, 9).
However, their onset at 8–11 mo after pristane treatment
was well after the establishment of renal disease (2), arguing
that the renal lesions may not be caused directly by anti-
dsDNA antibodies. Nevertheless, renal disease in pristane-
treated B6 IL-62/2 mice is milder than in IL-61/1 controls
(Richards, H.B., M. Satoh, M. Shaw, C. Libert, V. Poli,
and W.H. Reeves, unpublished data), consistent with the
idea that IL-6 itself may contribute to the development of
nephritis (42). Interestingly, although the levels of anti-
nRNP/Sm antibodies also were influenced by IL-6, their
frequency was not, suggesting that they may be regulated
differently from anti-DNA antibodies.
The different cytokine requirements for anti-dsDNA
and anti-Sm antibody production may help to explain dif-
ferences in the patterns of their expression seen clinically.
For example, low levels of antichromatin antibodies devel-
oped spontaneously in aged BALB/cAn1/1 mice but not in
IL-62/2 mice (Fig. 2), an observation that may be relevant
to the increased frequency of antinuclear antibodies (43)
and higher IL-6 production (44) in elderly people.
The extreme variability characteristic of anti-dsDNA an-
tibody levels (5) contrasts with the fact that the levels of
anti-Sm generally remain relatively stable over time. We
speculate that, as in pristane-induced lupus, anti-dsDNA
antibody production in human SLE may be IL-6 depen-
Figure 3. Anti-nRNP/Sm and anti-chromatin antibody ELISAs. Sera
from pristane treated IL-62/2 (n 5 28, d) or IL-61/1 (n 5 26, j) mice
and from PBS-treated IL-62/2 (n 5 10, s) or IL-61/1 (n 5 10, u) mice
0–8 mo after treatment were tested for anti-nRNP/Sm (A and B) and an-
tichromatin (C and D) antibodies by ELISA. (Top) Frequencies (%) of sera
containing IgG anti-nRNP/Sm (A) or antichromatin (B) autoantibodies
(defined as .3 SDs above the mean of negative controls). (Bottom) Levels
of anti-nRNP/Sm (B) or anti-chromatin (D) autoantibodies (in units).
Data represent the mean of all animals in each group.989 Richards et al. Brief Definitive Report
dent. Thus, anti-dsDNA/chromatin antibody levels might
be a surrogate marker for increased IL-6 production, which
is associated with active SLE (37). The induction of anti-
DNA antibodies in mice by lipopolysaccharide (45), a
potent inducer of IL-6 (46), raises the possibility that
microbial stimulation could trigger both IL-6 production
and anti-DNA autoantibody production. Indeed, pristane-
induced lupus is milder in specific pathogen–free than in
conventionally housed mice (12). In view of the importance
of anti-DNA antibodies and IL-6 in lupus nephritis, it may
be of interest to examine the role of microbial stimulation of
IL-6 production in the pathogenesis of lupus flares.
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